9 Meters Biopharma Inc. (NMTR)
NASDAQ: NMTR
· Real-Time Price · USD
0.07
-0.06 (-44.71%)
At close: Jul 25, 2023, 10:00 PM
9 Meters Biopharma Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
Fiscal Year | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
Period Ending | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Cash & Equivalents | 6.94M | 12.65M | 15.86M | 29.46M | 37.24M | 46.99M | 53.61M | 64.02M | 38.5M |
Short-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Long-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 8.98K | 7.28K | 23.54M | 5.58K | 5.58K | 5.58K | 5.58K | 5.58K | 5.58K |
Receivables | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Inventory | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Current Assets | 1.57M | 3.36M | 2.59M | 1.89M | 1.85M | 2.99M | 2.01M | 1.68M | 1.41M |
Total Current Assets | 9.2M | 33.02M | 18.45M | 31.35M | 39.09M | 49.99M | 56.48M | 65.78M | 39.98M |
Property-Plant & Equipment | 106.75K | 122.72K | 139.45K | 154.8K | 170.96K | 182.71K | 195.59K | 206.17K | 218.36K |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 115.73K | 130K | 23.68M | 160.38K | 176.53K | 188.29K | 201.17K | 211.75K | 223.94K |
Total Assets | 9.31M | 33.15M | 42.14M | 31.51M | 39.26M | 50.17M | 56.68M | 65.99M | 40.21M |
Account Payables | 4.23M | 5.05M | 1.44M | 2.33M | 1.91M | 2.43M | 1.32M | 1.64M | 1.37M |
Deferred Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Short-Term Debt | 5.13M | 19.68M | 2.71M | 58.17K | 56.46K | 54.8K | 53.19K | 51.62K | 50.1K |
Other Current Liabilities | 6.21M | 5.96M | 8.72M | 6.96M | 6.26M | 5.97M | 5.91M | 5.03M | 4.57M |
Total Current Liabilities | 15.58M | 30.7M | 12.86M | 9.34M | 8.22M | 8.46M | 7.28M | 6.72M | 5.99M |
Long-Term Debt | 34.77K | 51.4K | 15.81M | 83.19K | 98.39K | 113.14K | 127.46K | 141.36K | 154.85K |
Other Long-Term Liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Liabilities | 34.77K | 51.4K | 15.81M | 83.19K | 98.39K | 113.14K | 127.46K | 141.36K | 154.85K |
Total Liabilities | 15.61M | 30.75M | 28.67M | 9.42M | 8.32M | 8.57M | 7.41M | 6.86M | 6.14M |
Total Debt | 5.17M | 19.73M | 18.52M | 141.36K | 154.85K | 167.94K | 180.65K | 192.98K | 204.95K |
Common Stock | 1.43K | 1.3K | 1.3K | 25.91K | 25.82K | 25.82K | 25.55K | 25.22K | 21.63K |
Retained Earnings | -226.48M | -212.61M | -200.68M | -191.32M | -180.19M | -168.84M | -159.29M | -145.75M | -137.49M |
Comprehensive Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shareholders Equity | -6.3M | 2.4M | 13.46M | 22.09M | 30.94M | 41.6M | 49.27M | 59.14M | 34.07M |
Total Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |